Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study

References

• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
   PubMed Web of Science ®Google Scholar
• Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health. Nat Med. 2020;26(3):317–319.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. Jama. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Vetter P, Eckerle I, Kaiser L. Covid-19: a puzzle with many missing pieces. British Medical Journal Publishing Group; 2020.
   Google Scholar
• Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019 novel coronavirus: lessons from previous epidemics. JAMA. 2020;323(12):1129–1130.
   PubMed Web of Science ®Google Scholar
• COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University. 2020. Available from: https://coronavirusjhuedu/maphtml Last Updated at Beijing Time 7/26/ 2020
   Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–1207.
   Web of Science ®Google Scholar
• Shao L, Li X, Zhou Y, et al. Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19. Front Med (Lausanne). 2020;7:246.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481
   PubMed Web of Science ®Google Scholar
• Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. Bmj. 2020;368:m641.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chan JWM, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686–689.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Balkhy HH, Hayden FG, et al. Middle east respiratory syndrome. N Engl J Med. 2017;376(6):584–594.
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
   Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.
   PubMed Web of Science ®Google Scholar
• Rubino S, Kelvin N, Bermejo-Martin JF, et al. As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation. J Infect Developing Countries. 2020;14(3):265–267.
   Google Scholar
• Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–1228.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   Web of Science ®Google Scholar
• Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–344.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang J, Sheng H, et al. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019;90:25–80
   PubMed Web of Science ®Google Scholar
• Todorov I, Gospodinova M, Bocheva Y, et al. Serum amyloid A protein in the course of infectious mononucleosis. Ther Adv Infect Dis. 2019;6:2049936118811208.
   Web of Science ®Google Scholar
• Xie N, Li Z, Zuo R, et al. Serum SAA1 and APOE are novel indicators for human cytomegalovirus infection. Sci Rep. 2017;7(1):1–7.
   PubMedGoogle Scholar
• Yuan Z-Y, Zhang -X-X, Wu Y-J, et al. Serum amyloid A levels in patients with liver diseases. World J Gastroenterol. 2019;25(43):6440.
   PubMed Web of Science ®Google Scholar
• Ather JL, Dienz O, Boyson JE, et al. Serum Amyloid A3 is required for normal lung development and survival following influenza infection. Sci Rep. 2018;8(1):1–13.
   PubMedGoogle Scholar
• Yip TT, Chan JW, Cho WC, et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem. 2005;51(1):47–55.
   PubMed Web of Science ®Google Scholar
• Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Inter J Infect Dis. 2020;96:467–474
   PubMed Web of Science ®Google Scholar
• Li H, Xiang X, Ren H, et al. Serum amyloid A is a biomarker of severe Coronavirus disease and poor prognosis. J Infect. 2020;80(6):646–655.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• Sack GH Jr. Serum amyloid A - a review. Mol Med (Cambridge, MA). 2018;24(1):46.
   PubMedGoogle Scholar